vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and GSI TECHNOLOGY INC (GSIT). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $6.1M, roughly 1.8× GSI TECHNOLOGY INC). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -49.7%, a 73.2% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 12.2%). Over the past eight quarters, GSI TECHNOLOGY INC's revenue compounded faster (8.6% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Triad GSI is an American voting machine vendor based in Xenia, Ohio. Their main products are election-related computer hardware and software for counting ballots, as well as voter registration.
ABUS vs GSIT — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $6.1M |
| Net Profit | $2.5M | $-3.0M |
| Gross Margin | — | 52.7% |
| Operating Margin | 13.9% | -113.7% |
| Net Margin | 23.5% | -49.7% |
| Revenue YoY | 522.2% | 12.2% |
| Net Profit YoY | 112.7% | 25.0% |
| EPS (diluted) | $0.01 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $6.4M | ||
| Q2 25 | $10.7M | $6.3M | ||
| Q1 25 | — | $5.9M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | — | $4.5M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | $2.5M | $-2.2M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | — | $-4.0M | ||
| Q3 24 | — | $-5.5M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $-4.3M |
| Q4 25 | — | 52.7% | ||
| Q3 25 | — | 54.8% | ||
| Q2 25 | — | 58.1% | ||
| Q1 25 | — | 56.1% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 38.6% | ||
| Q2 24 | — | 46.3% | ||
| Q1 24 | — | 51.6% |
| Q4 25 | — | -113.7% | ||
| Q3 25 | — | -49.5% | ||
| Q2 25 | 13.9% | -34.6% | ||
| Q1 25 | — | -38.7% | ||
| Q4 24 | — | -74.9% | ||
| Q3 24 | — | -122.7% | ||
| Q2 24 | — | 23.1% | ||
| Q1 24 | — | -87.6% |
| Q4 25 | — | -49.7% | ||
| Q3 25 | — | -49.4% | ||
| Q2 25 | 23.5% | -35.3% | ||
| Q1 25 | — | -37.9% | ||
| Q4 24 | — | -74.4% | ||
| Q3 24 | — | -120.0% | ||
| Q2 24 | — | 23.1% | ||
| Q1 24 | — | -83.9% |
| Q4 25 | — | $-0.09 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | $0.01 | $-0.08 | ||
| Q1 25 | — | $-0.09 | ||
| Q4 24 | — | $-0.16 | ||
| Q3 24 | — | $-0.21 | ||
| Q2 24 | — | $0.04 | ||
| Q1 24 | — | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $70.7M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $83.6M |
| Total Assets | $103.3M | $98.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $70.7M | ||
| Q3 25 | — | $25.3M | ||
| Q2 25 | $37.4M | $22.7M | ||
| Q1 25 | — | $13.4M | ||
| Q4 24 | — | $15.1M | ||
| Q3 24 | — | $18.4M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $83.6M | ||
| Q3 25 | — | $38.6M | ||
| Q2 25 | $83.0M | $37.4M | ||
| Q1 25 | — | $28.2M | ||
| Q4 24 | — | $29.9M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $38.0M | ||
| Q1 24 | — | $36.0M |
| Q4 25 | — | $98.5M | ||
| Q3 25 | — | $52.0M | ||
| Q2 25 | $103.3M | $50.5M | ||
| Q1 25 | — | $43.3M | ||
| Q4 24 | — | $44.1M | ||
| Q3 24 | — | $47.4M | ||
| Q2 24 | — | $52.3M | ||
| Q1 24 | — | $42.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-7.9M |
| Free Cash FlowOCF − Capex | — | $-8.2M |
| FCF MarginFCF / Revenue | — | -134.4% |
| Capex IntensityCapex / Revenue | 0.0% | 4.9% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-12.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.9M | ||
| Q3 25 | — | $-887.0K | ||
| Q2 25 | $-15.7M | $-1.7M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-7.1M |
| Q4 25 | — | $-8.2M | ||
| Q3 25 | — | $-906.0K | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-7.2M |
| Q4 25 | — | -134.4% | ||
| Q3 25 | — | -14.1% | ||
| Q2 25 | — | -27.6% | ||
| Q1 25 | — | -28.3% | ||
| Q4 24 | — | -66.1% | ||
| Q3 24 | — | -76.6% | ||
| Q2 24 | — | -92.0% | ||
| Q1 24 | — | -139.0% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.96× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
GSIT
| Distribution | $5.6M | 92% |
| Other | $459.0K | 8% |
